-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CiW5bakNpA0iJjA3emxTegDnSDxN2ZK0YHCy36+BbUQp1ydunOMB6+hZfi9MMdfN dTl4pD7nT3KHadQ4f36ddg== 0000930413-05-004469.txt : 20050622 0000930413-05-004469.hdr.sgml : 20050622 20050622151543 ACCESSION NUMBER: 0000930413-05-004469 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20050622 DATE AS OF CHANGE: 20050622 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CASTLE & MORGAN HOLDINGS INC CENTRAL INDEX KEY: 0001278129 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-NONSTORE RETAILERS [5960] IRS NUMBER: 320104570 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-79983 FILM NUMBER: 05910068 MAIL ADDRESS: STREET 1: 1175 WALT WHITMAN ROAD STREET 2: SUITE 100 CITY: MELVILLE STATE: NY ZIP: 11747 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: R R BIOTECH PARTNERS LLC CENTRAL INDEX KEY: 0001295249 IRS NUMBER: 260083392 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 330 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-356-0509 MAIL ADDRESS: STREET 1: 330 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 SC 13D 1 c37967_sc13d.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 CASTLE & MORGAN HOLDINGS, INC.[GRAPHIC OMITTED] - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $0.001 per share - -------------------------------------------------------------------------------- (Title of Class of Securities) 148430 (CUSIP Number) Kenneth Rose, Esq. Morse, Zelnick, Rose & Lander, LLP 405 Park Avenue, Suite 1401 New York, New York 10022 Tel: (212) 838-5030 Fax: (212) 838-9190 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 13, 2005 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 148430 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). R&R Biotech Partners, LLC; 26-0083392 - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) ................................................................. (b) X ................................................................. - -------------------------------------------------------------------------------- 3. SEC Use Only ........................................................... - -------------------------------------------------------------------------------- 4. Source of Funds (See Instructions) (See item 3) AF ........................ - -------------------------------------------------------------------------------- 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) .................................................. - -------------------------------------------------------------------------------- 6. Citizenship or Place of Organization Delaware ........................................................................ - -------------------------------------------------------------------------------- Number of 7. Sole Voting Power 1,378,589 Shares ......................................... Beneficially ---------------------------------------------------------------- Owned by 8. Shared Voting Power Each ........................................ Reporting ---------------------------------------------------------------- Person 9. Sole Dispositive Power 1,378,589 With ..................................... ---------------------------------------------------------------- 10. Shared Dispositive Power ................................... - -------------------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned by Each Reporting Person 1,378,589 .............. - -------------------------------------------------------------------------------- 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ........................................................ - -------------------------------------------------------------------------------- 13. Percent of Class Represented by Amount in Row (11) 36.19% ........................ - -------------------------------------------------------------------------------- 14. Type of Reporting Person (See Instructions) OO ........................................................................... ........................................................................... - -------------------------------------------------------------------------------- ITEM 1. SECURITY AND ISSUER. This Schedule 13D relates to the common stock, par value $0.001 per share (the "Common Stock") of Castle & Morgan Holdings, Inc., whose principal executive offices are located at 180 Varick Street. 13th Floor, New York, NY 10014 (the "Issuer"). ITEM 2. IDENTITY AND BACKGROUND. (a) The name of the reporting person is R&R Biotech Partners, LLC ("R&R"). (b) The business address of the reporting person is 330 Madison Avenue, New York, NY 10017. (c) R&R was formed for the purpose of investing in biotechnology companies. (d) R&R has not been convicted in any criminal proceedings during the last five years. (e) R&R has not been a party to any civil proceedings during the last five years. (f) R&R is organized under the laws of the State of Delaware. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. R&R acquired the securities from certain selling shareholders ("Selling Shareholders") of the Issuer with funds received from its affiliate, Rodman & Renshaw, a registered broker-dealer. ITEM 4. PURPOSE OF TRANSACTION. Whereas the Issuer is a public shell company, the acquisition was made by R&R to acquire a controlling equity interest in the Issuer in contemplation of acquiring, in the future by merger, a company with a viable operating business. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) R&R is deemed to beneficially own all 1,378,589 shares, representing 36.19% of the outstanding shares of Common Stock. This percentage is based, as to the number of outstanding shares, upon the Issuer's statement as to the number of outstanding shares of Common Stock as set forth in its Form 10-QSB/A, filed with the Securities and Exchange Commission on May 19, 2005. (b) R&R has the sole power to vote or to direct the vote, and dispose or direct the disposition, of all 1,378,589 shares owned by it. (c) R&R acquired all 1,378,589 shares and an interest in a Convertible Note (the "Note") of the Issuer, held by certain of the Selling Shareholders in the principal amount of $52,920, from the Selling Shareholders as of June 13, 2005. The average per share price of the shares acquired was approximately $0.16. The transaction was effected by R&R delivering the purchase price to the Selling Shareholders and the Selling Shareholders assigning an interest in the Note, and delivering the shares, to R&R. (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock purchased by R&R. (e) Not applicable. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. None. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. A copy of the Securities Purchase Agreement has been filed as an exhibit to the Current Report on Form 8-K filed by the Issuer on June 17, 2005 and is incorporated herein by reference. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. June 20, 2005 R&R Biotech Partners, LLC By: /s/ Thomas G. Pinou ------------------------------ Thomas G. Pinou Treasurer -----END PRIVACY-ENHANCED MESSAGE-----